IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

SAN RAFAEL, Calif. & BARCELONA--(BUSINESS WIRE)--IMIDomics, Inc., a biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs), announced today the formation of an Immunology Advisory Board consisting of a number of scientific and industry luminaries with experience in developing and bringing to market new therapies targeting IMIDs.

“As we continue to refine our Precision Discovery Engine, move forward with identifying and pursuing targets for potential new treatments and forge key partnership within the pharmaceutical and biotechnology space, having this seasoned, respected and passionate group of advisors will be key to ensuring we’re maximizing the potential of IMIDomics to deliver meaningful results for IMID patients,” said Fred Craves, CEO of IMIDomics. “We are honored and excited to work closely with each of them and tap their unparalleled expertise.”

Members of the IMIDomics Immunology Advisory Board include:

• André Veillette, M.D.: Dr. Veillette is a world-recognized immunologist and medical oncologist who, over the past three decades, has done pioneering work on identifying and characterizing intracellular molecules and receptors that play critical roles in normal immune regulation. Dr. Veillete is a member of the COVID-19 Vaccine Task Force and the Long COVID Task Force of the Government of Canada.

• Arthur Weiss, M.D., Ph.D.: Dr. Weiss is the Ephraim P. Engleman Distinguished Professor of Rheumatology at the University of California San Francisco where he has been on faculty since 1985. From 1988 through 2011, he served as Chief of Rheumatology at UCSF. Dr. Weiss studies signal transduction in the immune system, focusing on the roles of tyrosine kinases and phosphatases in regulating lymphocyte activation and how abnormalities in tyrosine phosphorylation pathways lead to immunologically mediated diseases.

• Dan Littman, M.D., Ph.D.: Dr. Littman, is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the New York University School of Medicine and an investigator of the Howard Hughes Medical lnstitute. Dr. Littman investigates how microbiota and their products influence host immune responses, contributing to homeostasis or inflammatory disease. He serves on multiple academic and industry advisory boards and the Pfizer Board of Directors.

• Lewis Lanier, Ph.D.: Dr. Lanier is an American Cancer Society Professor, and J. Michael Bishop, MD, Distinguished Professor and Chairman of Microbiology and Immunology at the University of California San Francisco, and Director of the Parker Institute for Cancer Immunotherapy. His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses. He has served as President of the American Association of Immunologists and is a member of the National Academy of Sciences.

• Pablo Engel, M.D., Ph.D.: Dr. Engel is a Professor of Immunology and Head of the Immunology Unit in the Department of Biomedical Sciences at the University of Barcelona. His research is focused on lymphocyte cell-surface molecules and their role in the regulation of immune responses. In addition to his research, Pablo has been Secretary General of the European Federation of Immunological Societies (EFIS).

ABOUT IMIDOMICS, INC.

IMIDomics, Inc. is a privately held global biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs). Utilizing an exclusive commercial license with the Vall d’Hebron Hospital IMID Biobank’s to access anonymized data from more than 17,000 patients across 150 health centers, IMIDomics specializes in generating unique insights into IMID patient experiences, conditions and underlying disease mechanisms. This data forms the foundation of the IMIDomics Precision Discovery™ Engine which leverages state-of-the-art analytics, machine learning and bioinformatics expertise to uncover new insights about IMIDs based on precisely defined patient populations. These insights are enabling new discoveries for treatments, diagnostics and other innovations designed to address the unmet needs of people living with these complex and challenging diseases.

IMIDomics was founded in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Department at the Vall d’Hebron University Hospital, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology. Existing investors in IMIDomics include DNS Capital, Tao Capital, The Pritzker Organization, Evotec and Bristol Myers Squibb. To learn more about IMIDomics, please visit www.imidomics.com.

IMIDomics Press Contact:
Casey Blickenstaff at Real Chemistry
cblickenstaff@realchemistry.com